TITLE

Partnering in CHINA Best practices for selecting a central lab partner in this popular trial destination

AUTHOR(S)
DiCarlo, Renzo; Zhang, Jenny
PUB. DATE
April 2009
SOURCE
Applied Clinical Trials;Apr2009 Supplement, p14
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses the importance of partnering central laboratories to support drug development and help manage the complexities of clinical trials in China. It mentions that a strong relationship with a central lab may lead to a more effective and efficient use of study protocol design, appropriate assay and biomarkers. Moreover, it notes that a central lab partner can give insights on maximizing value from a trial and reduce costs associated with regulatory issues and logistic.
ACCESSION #
39235990

 

Related Articles

  • Biomarkers and Surrogate Endpoints in Clinical Drug Development. Rosenkranz, Bernd // Applied Clinical Trials;Jul2003, Vol. 12 Issue 7, p30 

    Focuses on the importance of selecting a suitable clinical biomarker in clinical drug development in the U.S. Validity of the primary variables in pivotal clinical trials; Identification of appropriate dose regimens for efficacy studies; Demonstration of a proof of concept of the study.

  • 'Critical Path' for drug development a priority.  // Formulary;Sep2004, Vol. 39 Issue 9, p458 

    Reports on the Critical Path Initiative to develop an applied science toolkit that will contain animal- and computer-based predictive models for drug evaluation, biomarkers for drug safety and effectiveness and clinical evaluation techniques in the United States. Use of the toolkit as a means...

  • Biomarkers From Bench to Bedside: Are We There Yet? Prakash, Kulkarni; Keser, Dean; Kaldjian, Eric; ffrench-Mullen, Jarlath // Drug Discovery & Development;Aug2006, Vol. 9 Issue 8, pS3 

    The article focuses on the emergence of a personalized medicine based on a patient's individual biological profile of molecular biomarkers. The new approach directs what drugs a patient should or should not receive in the duration of treatment. A valid biomarker is one that is widely accepted as...

  • Drug Target/Biomarker Discovery Applications Drive Tissue Microarrays. Walsh, Joseph // PharmaGenomics;Jun2004, Vol. 4 Issue 5, p12 

    According to a market study released by Select Biosciences, titled "Tissue Microarrays: Market Assessment and Opportunities," the market for tissue microarrays (TMAs) will increase from $13 million in 2002 to $163 million by 2008. A TMA is an assembly of many tissue samples into one block that...

  • Biomarkers in Alzheimer's disease drug development. Blennow, Kaj // Nature Medicine;Nov2010, Vol. 16 Issue 11, p1218 

    Biomarkers may be of great value in Alzheimer's disease drug development to select the most optimal drug candidates for large and expensive phase 3 clinical trials. Biomarkers will also be important to provide evidence that a drug affects the underlying pathophysiology of the disease, which,...

  • Drug-diagnostics co-development in oncology. Simon, Richard // Frontiers in Oncology;Dec2013, Vol. 3, p1 

    Developments in genomics are providing a biological basis for the heterogeneity of clinical course and response to treatment that have long been apparent to clinicians. The ability to molecularly characterize human diseases presents new opportunities to develop more effective treatments and new...

  • A Pathway and Approach to Biomarker Validation and Qualification for Osteoarthritis Clinical Trials. Hunter, David J.; Losina, Elena; Guermazi, Ali; Burstein, Deb; Lassere, Marissa N.; Kraus, Virginia // Current Drug Targets;May2010, Vol. 11 Issue 5, p536 

    This narrative review outlines the work done in other fields with regards biomarker validation and qualification and the lessons that we may learn from this experience. Defining a universally agreed upon path for biomarker validation and qualification is urgently needed to circumvent many of the...

  • Valuation of biomarkers. Hurko, Orest; Jones, Graham K. // Nature Reviews Drug Discovery;Apr2011, Vol. 10 Issue 4, p253 

    The article discusses the model to be used in valuing a non-surrogate biomarker programme. The model is based on a mathematical expression that calculates an expected value of a study. In this model, risks and cash flow associated with Phase III trials depend on the clinical results of the Phase...

  • Review of Pharmacological Treatment in Mood Disorders and Future Directions for Drug Development. Li, Xiaohua; Frye, Mark A; Shelton, Richard C // Neuropsychopharmacology;Jan2012, Vol. 37 Issue 1, p77 

    After a series of serendipitous discoveries of pharmacological treatments for mania and depression several decades ago, relatively little progress has been made for novel hypothesis-driven drug development in mood disorders. Multifactorial etiologies of, and lack of a full understanding of, the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics